Out of 2509 BCa patients from the METABRIC-TCGA database [30,31], 1242 fulfilled the requirements of the study, i.e., invasive ductal carcinoma of no special type (IDC, NST), available data on follow-up, FGFR2 gene mRNA, and hormonal receptor status, and were selected for the analysis (Figure S4). This evidence concerns the gene FGFR2 and invasive ductal breast carcinoma.